
Europe approves first gene therapy for haemophilia B
The Commission European has granted conditional marketing authorisation for etranacogene dezaparvovec (Hemgenix), the first and only gene therapy for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adults without a history of factor IX inhibitors. The approval means that the product will now be available in all countries of […]